Read the two bullets ITM placed at the top of its own release in order. No clinical or nonclinical concerns and no additional data requested. Then: CMC and third-party commercial facility inspection items. The drug is not the problem. COMPETE hit its endpoint, the results are published in The Lancet, and the agency did not touch any of it. What stopped this approval is a facility ITM does not own. That is the second time in four days a US regulatory outcome has turned on a third-party manufacturing site rather than on evidence.

• Set this beside Scholar Rock and you have one test with two answers. Scholar Rock’s apitegromab application named two fill-finish facilities. When the FDA classified one of them as Official Action Indicated on 7 August, the company removed it, carried on with the second, and its action date did not move. ITM received its letter the same day and now has to resubmit. Same week, same category of finding, and the difference between a release about progress and a complete response letter was redundancy present at the moment of filing.
• Do not read that as a planning failure, because radiopharma cannot dual-source the way biologics can. No-carrier-added lutetium-177 production and radiolabelling capacity is genuinely scarce, the isotope decays while it ships, and the list of qualified facilities is short. Naming a second site is a strategy readily available to a company filling vials of antibody and largely unavailable to one distributing a decaying isotope against a clock. That constraint is exactly why the manufacturing and distribution network is the moat in this field, and it is why Curium agreed to pay up to eight billion dollars for Lantheus rather than build one.
• What to watch: the resubmission classification, because a Class 1 review runs two months and a Class 2 runs six, and ITM has not indicated which it expects. Then establish whether the remedy sits with the third party remediating its site or with ITM qualifying an alternative, since those are very different timelines and only one of them is inside ITM’s control. Note the sequence without over-reading it: Lumara Bio, the oncology division built around this asset, was announced eleven days before the letter arrived, which tells you the company was preparing to commercialise rather than expecting to wait.